CA2946669A1 - Ion channel modulators & uses thereof - Google Patents

Ion channel modulators & uses thereof Download PDF

Info

Publication number
CA2946669A1
CA2946669A1 CA2946669A CA2946669A CA2946669A1 CA 2946669 A1 CA2946669 A1 CA 2946669A1 CA 2946669 A CA2946669 A CA 2946669A CA 2946669 A CA2946669 A CA 2946669A CA 2946669 A1 CA2946669 A1 CA 2946669A1
Authority
CA
Canada
Prior art keywords
antibody
chain variable
variable region
prt prt
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2946669A
Other languages
English (en)
French (fr)
Inventor
Wendy A. Williams
Clare Jones
James BUTTON
John LINLEY
Ling Huang
Harm Jan SNIJDER
Yoko Shibata
Sudharsan SRIDHARAN
Maria Groves
Claire Dobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of CA2946669A1 publication Critical patent/CA2946669A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2946669A 2014-05-02 2015-05-02 Ion channel modulators & uses thereof Abandoned CA2946669A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987929P 2014-05-02 2014-05-02
US61/987,929 2014-05-02
PCT/EP2015/059633 WO2015166105A2 (en) 2014-05-02 2015-05-02 Ion channel modulators and uses thereof

Publications (1)

Publication Number Publication Date
CA2946669A1 true CA2946669A1 (en) 2015-11-05

Family

ID=53055033

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2946669A Abandoned CA2946669A1 (en) 2014-05-02 2015-05-02 Ion channel modulators & uses thereof

Country Status (8)

Country Link
US (2) US10654926B2 (enExample)
EP (2) EP4001310A3 (enExample)
JP (2) JP2017515473A (enExample)
AU (1) AU2015254558B2 (enExample)
BR (1) BR112016025450A2 (enExample)
CA (1) CA2946669A1 (enExample)
ES (1) ES2899754T3 (enExample)
WO (1) WO2015166105A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3674327A4 (en) * 2018-02-01 2021-05-05 Nanjing Iaso Biotherapeutics Co., Ltd. CHEMICAL ANTIGENIC RECEPTOR (CAR) BINDING TO BCMA AND ITS APPLICATIONS
WO2020092883A1 (en) 2018-11-02 2020-05-07 Stc.Unm Therapeutic antibody fragments, making's and use's methods
WO2020186158A2 (en) * 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
US12123814B1 (en) * 2019-06-14 2024-10-22 Pierce Biotechnology, Inc. G- protein coupled receptor extraction formulations
WO2021041194A1 (en) * 2019-08-23 2021-03-04 Unm Rainforest Innovations Non-opioid compositions and therapies for pain management
PH12022551211A1 (en) * 2019-11-18 2023-10-02 Janssen Biotech Inc Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
CA3195817A1 (en) * 2020-10-16 2022-04-21 Brian Scott GARRISON Chimeric receptors and methods of use thereof
CN114685657B (zh) * 2020-12-31 2024-08-16 康诺亚生物医药科技（成都）有限公司 一种功能增强型抗体阻断剂的开发及其应用
US20250059273A1 (en) * 2021-12-16 2025-02-20 Unm Rainforest Innovations Humanized non-opioid composition and therapies for pain management

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6242216B1 (en) * 1997-11-14 2001-06-05 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X2 and P2X4, and methods of production and use thereof
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
US20050074819A1 (en) * 2003-10-01 2005-04-07 Japan Health Sciences Foundation Screening method of drug for treatment of neuropathic pain
US20080287467A1 (en) * 2004-05-06 2008-11-20 Gen Tamura Therapeutic Agent for Respiratory Diseases
US8470814B2 (en) 2009-02-16 2013-06-25 Nippon Chemiphar Co., Ltd. Diazepinedione derivative
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування

Also Published As

Publication number Publication date
US10654926B2 (en) 2020-05-19
ES2899754T3 (es) 2022-03-14
US20200247885A1 (en) 2020-08-06
EP4001310A3 (en) 2022-08-10
JP2017515473A (ja) 2017-06-15
US20170166634A1 (en) 2017-06-15
AU2015254558A1 (en) 2016-12-08
EP3137501A2 (en) 2017-03-08
JP2020018307A (ja) 2020-02-06
EP4001310A2 (en) 2022-05-25
WO2015166105A2 (en) 2015-11-05
BR112016025450A2 (pt) 2017-12-12
WO2015166105A3 (en) 2015-12-30
EP3137501B1 (en) 2021-09-29
AU2015254558B2 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
US20200247885A1 (en) P2x4 antibodies & uses thereof
US20240228631A9 (en) Tetravalent FZD and WNT Co-receptor Binding Antibody Molecules and Uses Thereof
AU2019263850A1 (en) High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
US12365735B2 (en) Anti-KLRG1 antibodies
KR20240026496A (ko) 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체
IL302586A (en) Polypeptide constructs selectively binding to cldn6 and cd3
US20240417452A1 (en) Anti-mesothelin nanobodies and use thereof
KR20200068601A (ko) 엔도텔린 수용체 a 활성 조절 항체
TW202432596A (zh) 針對磷脂醯肌醇蛋白聚醣3的雙特異性抗體及其應用
WO2023250402A2 (en) Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2022127066A9 (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
US20260070966A1 (en) Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof
US20250304687A1 (en) Multispecific antibodies targeting cd79b/cd3 and the uses thereof
US20250304679A1 (en) Multispecific antibodies targeting cd79b and cd3 and the uses thereof
KR102934267B1 (ko) 항-klrg1 항체
CN119585311A (zh) 结合大麻素受体cb1的抗体及其用途
WO2024149237A1 (zh) TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
KR20260005790A (ko) 항-blt1 항체 및 이의 용도
EA049153B1 (ru) Антитела к klrg1

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200420

EEER Examination request

Effective date: 20200420

FZDE Discontinued

Effective date: 20230728